Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push
NEW YORK, April 1 —
Eli Lilly agreed to acquire Centessa Pharmaceuticals plc (CNTA) for up to $7.8bn, paying $6.3bn upfront to capture the biotech's orexin receptor pipeline.
- Total deal value: up to $7.8bn, with $6.3bn in upfront cash and the remainder in contingent value rights
- CNTA shares hit an all-time high post-announcement but still trade at a ~38% discount to the full deal price
- Watch for: regulatory and antitrust clearance timeline, plus CVR milestone triggers that unlock the remaining $1.5bn
Why It Matters
The acquisition gives Lilly a direct play in sleep-wake disorder treatments, a therapeutic area where demand is rising and competition remains thin. Centessa's orexin receptor agonist pipeline fills a gap Lilly could not easily build organically. The $6.3bn upfront commitment signals high conviction from a buyer that has been selective with neuroscience M&A.
For CNTA shareholders, the deal reprices a company generating just $15mn in trailing twelve-month revenue at a massive premium. The stock's negative forward P/E of -24.2x reflects a pre-revenue biotech profile — Lilly is paying for clinical-stage assets, not current earnings. Options activity has spiked as traders position around the spread between the current share price of $39.72 and the implied deal value.
The ~38% gap between where CNTA trades and the full $7.8bn consideration is wider than typical pharma takeouts. That spread prices in two distinct risks: standard regulatory approval for deal closure and the probability that CVR milestones are actually met. Investors buying here are making a bet on both.
The Risk
Antitrust review or an adverse regulatory ruling could delay or block the transaction, collapsing the merger premium. Separately, the $1.5bn in CVRs depends on specific clinical and commercial milestones — if Centessa's pipeline data disappoints post-close, acquirer shareholders absorb the loss, but CNTA holders who sold at market never collect the full consideration. Any competing bid, while unlikely given Lilly's scale, would reset the calculus entirely.
Centessa Pharmaceuticals does not yet have a dedicated research page on Basis Report — visit the CNTA stock page to generate a full analysis including pipeline valuation and deal-spread tracking.
Basis Report does not hold positions in securities discussed. This is not investment advice.